Epigenetic drug discovery and tools
 

Drug Discovery

CellCentric is a drug discovery company developing small molecule inhibitors for cancer.

 

CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the most aggressive form of the disease (castrate-resistant prostate cancer), and overcome many of the resistance mechanisms seen with existing drugs.

 

The programme also has potential clinical utility in other cancers including non-small cell lung, breast and colon cancer.